ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

CANF Can Fite BioPharma Ltd

2,725
0,015 (0,55%)
21 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Can Fite BioPharma Ltd CANF AMEX Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,015 0,55% 2,725 18:36:04
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
2,77 2,62 2,78 2,725 2,71
mais cotações »

Notícias Recentes

Data Hora Fonte Título
10/06/202408:00BWCan-Fite Received IRB Approval for the Treatment of..
05/06/202408:00BWCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase..
29/05/202408:00BWIndependent Scientists Published a Review Article..
27/05/202408:00BWCan-Fite to Participate in Partnering Meetings at Bio..
23/05/202408:00BWJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
13/05/202408:00BWCan-Fite: 75 Oncologists and Coordinators from Europe US and..
09/05/202408:00BWCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat..
06/05/202408:00BWCan-Fite Received Notice of Allowance from the European..
25/04/202408:00BWLong-term Complete Response to Can-Fite's Namodenoson in..
15/04/202408:00BWCan-Fite: Scientific Article Published by KOL Presents..
03/04/202408:00BWCan-Fite: Submits FDA with an IND Application to Conduct..
28/03/202408:00BWCan-Fite Reports 2023 Financial Results and Clinical Update
11/03/202408:00BWNamodenoson Treatment for Pancreatic and Liver Cancer: Data..
28/02/202409:00BWCan-Fite Broadens its Strong Intellectual Property (IP) for..
30/01/202409:00BWCan-Fite Expands the Out-Licensing Deal with Ewopharma to..
29/01/202409:00BWCan-Fite: Top Scientific Journal Published Positive Data..
20/12/202309:00BWThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular..
18/12/202309:00BWCan-Fite Received FDA Positive Response to Psoriasis..
04/12/202309:00BWCan-Fite’s Namodenoson for the Treatment of Pancreatic..
30/11/202309:00BWCan-Fite Reports Third Quarter 2023 Financial Results and..
21/11/202315:53GLOBECan-Fite Announces Exercise of Warrants for Approximately..
21/11/202309:00BWCan-Fite: Complete Response and 6.9 Years Overall Survival..
01/11/202308:00BWCan-Fite Issues Business Update: All Clinical Programs and..
30/10/202308:00BWCan Fite: Namodenoson Inhibits Pancreatic Carcinoma..
26/10/202308:00BWCan-Fite to Harness Artificial Intelligence to Develop Novel..
09/10/202308:00BWCan-Fite to Share its Rare Genetic Disease Lowe Syndrome..
27/09/202308:00BWCan-Fite Novel Approach for the Treatment of Pancreatic..
07/09/202308:00BWCan-Fite to Share with Investors Latest Oncology and Rare..
31/08/202308:00BWCan-Fite Reports Second Quarter 2023 Financial Results &..
24/08/202308:10BWCan-Fite Enters Rare Genetic Disease Field Based on..
18/08/202308:00BWCan-Fite Submitted to FDA a Pediatric Plan to Allow..
17/07/202308:00BWCan-Fite: Granted Breakthrough Abstract Award for..
29/06/202308:00BWCan-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson..